SynAct?Pharma AB announced that the Nomination Committee in preparation for the Annual General Meeting 2022 on May 20, 2022, has been appointed. Pursuant to the instruction and charter for the Nomination Committee adopted at the Annual General Meeting held on May 21, 2021, the Nomination Committee shall consist of four members, representing the three largest shareholders as per end of September, together with the chairman of the Board of Directors. Based on the above, the Nomination Committee for the Annual General Meeting 2022 has been established to consist of the following persons: Pernille Singer, appointed by Bioinvest ApS; Jens Bager, appointed by GL Capital AB; Steen Christensen, appointed by Next Stage Ventures ApS; Torbj?rn Bjerke, Chairman of the Board of Directors. The members have appointed Jens Bager to be its chairman.